Ulcerative Colitis Market Overview:
Ulcerative Colitis (UC) is a chronic, debilitating disease that affects large intestine or colon. The cause of ulcerative colitis is unknown however, researchers believe that it is an exaggerated immune response to a microbial trigger. UC is characterized by inflammation in the colon, and its symptoms include blood in the stool, diarrhea, and abdominal pain. As per Pfizer Inc., UC affects about one million people in the U.S. each year. The treatment of UC includes traditional therapies such as drugs made of tumor necrosis factor (TNF) inhibitors and small molecule. The global ulcerative colitis market accounted for $4,785 million in 2016 and is expected to reach $7,455 million by 2023, registering a CAGR of 6.5% from 2017 to 2023.
The report segments the global ulcerative colitis market based on disease type, molecule type, and route of administration. Based on molecule type, the market is categorized as biologics and small molecules. In terms of disease type, the market is divided into mild, moderate, and severe ulcerative colitis. Based on route of administration, the market is bifurcated into oral and injectables. Regionally, the market is analyzed in North America, Europe, Asia-Pacific, and LAMEA.
Global Ulcerative Colitis Market Segmentation
Drivers, Restraints & Opportunities
The factor that drive the growth of global ulcerative colitis market are growing prevalence of ulcerative colitis disease that affects millions of people globally. In addition, huge R&D and investment done by key players towards development of novel therapies for UC treatment and rise in government and non-government organizations towards research in biologics further fuels the market growth. However, patent expiry of drugs and stringent government regulations towards approval of biosimilars restrain the market growth. Unmet needs in the treatment of UC provide lucrative growth opportunities for the growth of the market.
Ulcerative Colitis Market: Drivers & Restraints
India Ulcerative Colitis Market
The high prevalence of ulcerative colitis disease in India drives the growth of the ulcerative colitis market. Moreover, healthcare infrastructural advancements and expansion of drug development sector further fuels the market growth in the country. In addition, robust government initiative toward improvement of healthcare facilities through favorable insurance schemes is anticipated to provide lucrative growth opportunities in the country. The ulcerative colitis market in India is expected to exhibit the CAGR of 7.1% from 2016 to 2023.
India Ulcerative Colitis Market, 2016-2023 ($Million)
The key players of the global ulcerative colitis market are Johnson & Johnson, GlaxoSmithKline plc, Eli Lilly and Co., Sanofi Aventis A/S, AstraZeneca plc, Merck & Co., Inc., InDex Pharmaceuticals Holding AB, Ajinomoto Pharmaceuticals Co., Ltd., and Abbott Laboratories. The other prominent players in the value chain include Avaxia Biologics Inc., BioLineRx Ltd., Celgene Corporation, Mitsubishi Tanabe Pharma Corporation, Salix Pharmaceuticals, Inc.
Key Benefits :
- The study provides an in-depth analysis of the global ulcerative colitis market and the current trends and future estimations to elucidate the imminent investment pockets.
- Comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
- The report presents quantitative analysis of the market from 2016 to 2023 to enable stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the market based on product assists to understand the trends in the industry.
- Key market players and their strategies are thoroughly analyzed to understand the competitive outlook of the industry.
Ulcerative Colitis Market Key Segments:
By Disease Type
- Mild Ulcerative Colitis
- Moderate Ulcerative Colitis
- Severe Ulcerative Colitis
By Molecule Type
- Small Molecules
By Route of Administration
- North America
- Rest of Europe
- South Korea
- Rest of Asia-Pacific
- Saudi Arabia
- South Africa
- Rest of LAMEA